Ascendis Pharma A/S (NASDAQ:ASND) increased significantly to $113.50. Barchart.com posted the move on Mar, 4. It has $4.78 billion market cap. The company’s valuation will be $239.10 million more at $119.18 target.

On March, 27 is expected Ascendis Pharma A/S (NASDAQ:ASND)’s earnings report, as reported by Faxor. This year’s EPS analyst estimate is expected to be $-1.18. That is 9.26 % down compareed to $-1.08 EPS for last year. 25.53 % negative EPS growth is what analysts predict. $-0.94 EPS was reported for last quarter.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Total analysts of 2 have positions in Ascendis Pharma (NASDAQ:ASND) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 24, 2019 according to StockzIntelligence Inc Ascendis Pharma has 2 analyst reports. On Thursday, January 24 the firm has “Outperform” rating given by Leerink Swann.

For more Ascendis Pharma A/S (NASDAQ:ASND) news published recently go to: Benzinga.com, Globenewswire.com, Benzinga.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “50 Stocks Moving In Monday’s Mid-Day Session – Benzinga” published on March 04, 2019, “Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference – GlobeNewswire” on December 21, 2018, “Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings – Benzinga” with a publish date: November 28, 2018, “Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences – GlobeNewswire” and the last “Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29 – GlobeNewswire” with publication date: August 15, 2018.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs.The firm is worth $4.78 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.Currently it has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.